With an SBIR Phase II grant in hand, Michigan startup Parabricks is adding both speed and AI to variant calling as it eyes a Series A round next year.
The chatbot developed with Clear Genetics follows up with patients after genetic testing and educates family members at risk for inheriting the same mutations.
The companies announced a strategic venture to provide comprehensive biomarker profiling to empower clinical trials in the immuno-oncology space.
Franklin, an AI-driven variant classification tool, is helping Sanford Imagenetics reduce variants of unknown significance in its new ACMG-59 genotyping test.
While "genomical" has not supplanted "astronomical" in the lexicon, geneticist Gene Robinson believes data scientists understand the sheer size of genomic information.
As part of an NIH SBIR grant, Genomenon is automating the curation of medical literature in its Mastermind variant interpretation software.
Built by two of the creators of Nextflow, former Techstars company Lifebit makes scaleable genomic analysis technology that runs in the cloud.
IBM's supercomputing platform will continue to provide AI support to advanced cancer patients at VA medical centers for at least another year.
NuMedii will use its AI technology in combination with single-cell data to identify biomarkers and therapeutics for idiopathic pulmonary fibrosis.
The companies plan to combine blockchain technology, artificial intelligence, and genomics for medical analytics.
Senator Elizabeth Warren (D-Mass.) has released the results of a genetic ancestry analysis, the Boston Globe reports.
Retraction Watch's Ivan Oransky and Adam Marcus report that Harvard Medical School and Brigham and Women's Hospital have recommended that more than 30 papers from a former researcher be retracted.
Thomas Steitz, who won the 2009 chemistry Nobel Prize for his ribosome work, has died, the Washington Post reports.
In PLOS this week: mechanisms for genes implicated in coronary artery disease, rumen microbes and host genetics influence cow methane production, and more.